Atlas Trials

Dense Deposit Disease

14 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Dense Deposit Disease

RecordFirmDate
Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis (NCT05067127)Apellis Pharmaceuticals, Inc.2021-11-12
Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy (NCT04183101)Region Skane2020-10-01
Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN) Enrolled in the ACH471-205 Study (NCT03723512)Mario Negri Institute for Pharmacological Research2018-12-06
A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471 (NCT03459443)Alexion Pharmaceuticals, Inc.2018-06-20
A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G) (NCT03369236)Alexion Pharmaceuticals, Inc.2018-06-12
Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies (NCT03453619)Apellis Pharmaceuticals, Inc.2018-02-26
A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN (NCT03124368)Alexion Pharmaceuticals, Inc.2017-08-09
TP10 Use in Patients With C3 Glomerulopathy (C3G) (NCT02302755)University of Iowa2014-11-01
Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease (NCT01791686)Celldex Therapeutics2013-01-01
Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy (NCT01221181)Columbia University2010-07-01
National Registry of Rare Kidney Diseases (NCT06065852)UK Kidney Association2009-11-06
Sulodexide Treatment in Patients With Dense Deposit Disease (NCT00583427)University of Iowa2007-12-01
C3G/Primary IC-MPGN EAP (NCT04729062)Apellis Pharmaceuticals, Inc.

Track Dense Deposit Disease automatically

Every clearance here is in the API, with alerts when new ones post.